Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy

Journal of Clinical Oncology

Volumn 27, Issue 6, 2009, Pages 857-871

  Hildebrandt, Michelle A T ^a   Yang, Hushan ^a   Hung, Mien Chie ^a   Izzo, Julie G ^a   Huang, Maosheng ^a   Lin, Jie ^a   Ajani, Jaffer A ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE B BETA; TAXANE DERIVATIVE;

ADENOCARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SURVIVAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RADIOTHERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 60849109531     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.6297     Document Type: Article

References (38)

1. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, Ga, American Cancer Society, 2008
2. Brenner B, Ilson DH, Minsky BD: Treatment of localized esophageal cancer. Semin Oncol 31: 554-565, 2004
3. Iyer R, Wilkinson N, Demmy T, et al: Controversies in the multimodality management of locally advanced esophageal cancer: Evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 11:665-673, 2004
4. Urba S: Esophageal cancer: Preoperative or definitive chemoradiation. Ann Oncol 15:iv93-iv96, 2004 (suppl 4)
5. Tepper JE, Krasna MJ, Niedzwiecki D: Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781. J Clin Oncol 24:181s, 2006 (suppl; abstr 4012)
6. Burmeister BH, Smithers BM, Gebski V, et al: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 6:659-668, 2005
7. Gebski V, Burmeister B, Smithers BM, et al: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8:226-234, 2007
8. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467, 1996
9. Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313, 2001
10. Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491, 1999
11. Wu X, Gu J, Wu TT, et al: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789-3798, 2006
12. Nicholson KM, Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14:381-395, 2002
13. Bellacosa A, Kumar CC, Di Cristofano A, et al: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 94:29-86, 2005
14. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000
15. Manning BD, Cantley LC: AKT/PKB signaling: Navigating downstream. Cell 129:1261-1274, 2007
16. Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39, 1998
17. Sagatys E, Garrett CR, Boulware D, et al: Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Hum Pathol 38:1526-1531, 2007
18. Hou G, Xue L, Lu Z, et al: An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 253:236-248, 2007
19. Lee S, Choi EJ, Jin C, et al: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97:26-34, 2005
20. Liu LZ, Zhou XD, Qian G, et al: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67:6325-6332, 2007
21. Kim SH, Juhnn YS, Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 1095:82-89, 2007
22. Gagnon V, Van Themsche C, Turner S, et al: Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13:259-271, 2008
23. Yang X, Fraser M, Moll UM, et al: Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66:3126-3136, 2006
24. Murakami D, Tsujitani S, Osaki T, et al: Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric Cancer 10:45-51, 2007
25. Chirieac LR, Swisher SG, Ajani JA, et al: Post-therapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103:1347-1355, 2005
26. Wu TT, Chirieac LR, Abraham SC, et al: Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome. Am J Surg Pathol 31:58-64, 2007
27. Consortium TIH: A haplotype map of the human genome. Nature 437:1299-1320, 2005
28. de Bakker PI, Yelensky R, Pe'er I, et al: Efficiency and power in genetic association studies. Nat Genet 37:1217-1223, 2005
29. Alessi DR, James SR, Downes CP, et al: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261-269, 1997
30. Tee AR, Fingar DC, Manning BD, et al: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99:13571-13576, 2002
31. Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-2963, 2004
32. Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932, 1999
33. Suzuki H, Freije D, Nusskern DR, et al: Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58:204-209, 1998
34. Saal LH, Gruvberger-Saal SK, Persson C, et al: Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40:102-107, 2008
35. Hu YC, Lam KY, Tang JC, et al: Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas. Mol Pathol 52:353-356, 1999
36. Chang MS, Lee HS, Lee BL, et al: Differential protein expression between esophageal squamous cell carcinoma and dysplasia, and prognostic significance of protein markers. Pathol Res Pract 201:417-425, 2005
37. Tachibana M, Shibakita M, Ohno S, et al: Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 94:1955-1960, 2002
38. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12:9-22, 2007